drugset
drugset / Trial / NCT04631588

Intradermal (ID) BOTOX in the Treatment of Facial Fine Lines

NCT04631588 ↗

Phase 1 Completed 172 enrolled Allergan
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The main objective of this study is to assess safety and tolerability of Intradermal (ID) BOTOX in participants with facial fine lines.

Timeline

Start
2020-11-16
Primary completion
2021-11-03
Completion
2021-11-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic — Other

Indications

No indication recorded.